aluates Reports

$ 0.0

Automative

Global Peptide Cancer Vaccine Market Research Report 2026

Published Date: 2026-02-10

Report Code: QYRE-Auto-1L12300

Global Peptide Cancer Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2022 2028

BUY CHAPTERS

Global Peptide Cancer Vaccine Market Research Report 2026

Code: QYRE-Auto-1L12300

Report

2026-02-10

Pages:113

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Peptide Cancer Vaccine Market Size

The global Peptide Cancer Vaccine market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of 19.8% from 2026 to 2032.

Peptide Cancer Vaccine Market

Peptide cancer vaccines are innovative immunotherapy products designed based on specific tumor-associated antigen peptides. By delivering selected peptide sequences into patients, these vaccines activate T cells within the immune system to recognize and attack tumor cells, achieving targeted anti-cancer effects. Compared to traditional therapies, peptide vaccines offer strong specificity, low side effects, and ease of production, and can be combined with other immunotherapies or chemotherapies to enhance treatment efficacy. With advancements in molecular biology and immunology, peptide cancer vaccines demonstrate broad potential in personalized treatments and applications across multiple tumor types, marking a significant breakthrough and emerging trend in the field of tumor immunotherapy.

The global increase in cancer patient populations drives strong demand for effective, safe, and personalized treatment solutions. Annual reports from leading biopharmaceutical companies highlight intensified investments in peptide cancer vaccine R&D, fostering technological innovation and clinical trial progress to strengthen market competitiveness. Governments worldwide support innovative medical technologies through policies and funding, accelerating peptide vaccine development and commercialization. The strong specificity and combinational therapy potential of peptide vaccines meet diverse needs across cancer types and patient populations, especially demonstrating value in refractory and recurrent tumors. The widespread adoption of precision medicine concepts and advances in bioinformatics-aided design further enhance R&D efficiency and market penetration.

The peptide cancer vaccine market faces challenges including high technical complexity, lengthy development cycles, and stringent clinical validation requirements. Regulatory policies and approval processes vary across countries and regions, increasing difficulty and cost for international market expansion. Market competition intensifies amid coexistence of traditional therapies and multiple emerging immunotherapies, requiring continuous innovation to maintain leadership. High R&D investment and production costs limit participation of some small and medium enterprises and broader product accessibility. Uncertainties in efficacy and safety necessitate strengthened clinical data support and risk management to ensure market acceptance and long-term competitiveness.

Future downstream demand for peptide cancer vaccines will exhibit personalization, diversification, and integration. Major comprehensive hospitals and oncology centers serve as primary markets, emphasizing treatment efficacy, safety, and synergy with existing therapies. Patient demand for precise and low-side-effect innovative treatments fuels rapid growth in personalized peptide vaccine customization and combination therapies. Advances in companion diagnostics and biomarkers enable more precise patient matching, maximizing therapeutic outcomes. Suppliers must continually enhance R&D capabilities and service quality to meet complex and evolving clinical needs and regulatory environments.

This report delivers a comprehensive overview of the global Peptide Cancer Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peptide Cancer Vaccine. The Peptide Cancer Vaccine market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes by Pipeline, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Peptide Cancer Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Pipeline, by Application, and by region.

Market Segmentation

Scope of Peptide Cancer Vaccine Market Report

Report Metric	Details
Report Name	Peptide Cancer Vaccine Market
CAGR	19.8%
Segment by Pipeline	ITK-1 GRN-1201 TPIV200 TPIV110 UV1 Galinpepimut-S TARP 27-35 HER-Vaxx Vx-001 Others
Segment by Application	Breast Cancer Lung Cancer Melanoma Prostate Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals, OncoTherapy Science
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Pipeline, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Peptide Cancer Vaccine companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Pipeline, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Peptide Cancer Vaccine Market report?

Ans: The main players in the Peptide Cancer Vaccine Market are Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals, OncoTherapy Science

What are the Application segmentation covered in the Peptide Cancer Vaccine Market report?

Ans: The Applications covered in the Peptide Cancer Vaccine Market report are Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Pipeline

1.2.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline: 2021 vs 2025 vs 2032

1.2.2 ITK-1

1.2.3 GRN-1201

1.2.4 TPIV200

1.2.5 TPIV110

1.2.6 UV1

1.2.7 Galinpepimut-S

1.2.8 TARP 27-35

1.2.9 HER-Vaxx

1.2.10 Vx-001

1.3 Market by Application

1.3.1 Global Peptide Cancer Vaccine Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Breast Cancer

1.3.3 Lung Cancer

1.3.4 Melanoma

1.3.5 Prostate Cancer

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Peptide Cancer Vaccine Market Perspective (2021–2032)

2.2 Global Peptide Cancer Vaccine Growth Trends by Region

2.2.1 Global Peptide Cancer Vaccine Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Peptide Cancer Vaccine Historic Market Size by Region (2021–2026)

2.2.3 Peptide Cancer Vaccine Forecasted Market Size by Region (2027–2032)

2.3 Peptide Cancer Vaccine Market Dynamics

2.3.1 Peptide Cancer Vaccine Industry Trends

2.3.2 Peptide Cancer Vaccine Market Drivers

2.3.3 Peptide Cancer Vaccine Market Challenges

2.3.4 Peptide Cancer Vaccine Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peptide Cancer Vaccine Players by Revenue

3.1.1 Global Top Peptide Cancer Vaccine Players by Revenue (2021–2026)

3.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Players (2021–2026)

3.2 Global Top Peptide Cancer Vaccine Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Peptide Cancer Vaccine Revenue

3.4 Global Peptide Cancer Vaccine Market Concentration Ratio

3.4.1 Global Peptide Cancer Vaccine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peptide Cancer Vaccine Revenue in 2025

3.5 Global Key Players of Peptide Cancer Vaccine Head Offices and Areas Served

3.6 Global Key Players of Peptide Cancer Vaccine, Products and Applications

3.7 Global Key Players of Peptide Cancer Vaccine, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Peptide Cancer Vaccine Breakdown Data by Pipeline

4.1 Global Peptide Cancer Vaccine Historic Market Size by Pipeline (2021–2026)

4.2 Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (2027–2032)

5 Peptide Cancer Vaccine Breakdown Data by Application

5.1 Global Peptide Cancer Vaccine Historic Market Size by Application (2021–2026)

5.2 Global Peptide Cancer Vaccine Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Peptide Cancer Vaccine Market Size (2021–2032)

6.2 North America Peptide Cancer Vaccine Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Peptide Cancer Vaccine Market Size by Country (2021–2026)

6.4 North America Peptide Cancer Vaccine Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Peptide Cancer Vaccine Market Size (2021–2032)

7.2 Europe Peptide Cancer Vaccine Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Peptide Cancer Vaccine Market Size by Country (2021–2026)

7.4 Europe Peptide Cancer Vaccine Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Peptide Cancer Vaccine Market Size (2021–2032)

8.2 Asia-Pacific Peptide Cancer Vaccine Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Peptide Cancer Vaccine Market Size by Region (2021–2026)

8.4 Asia-Pacific Peptide Cancer Vaccine Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Peptide Cancer Vaccine Market Size (2021–2032)

9.2 Latin America Peptide Cancer Vaccine Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Peptide Cancer Vaccine Market Size by Country (2021–2026)

9.4 Latin America Peptide Cancer Vaccine Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peptide Cancer Vaccine Market Size (2021–2032)

10.2 Middle East & Africa Peptide Cancer Vaccine Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Peptide Cancer Vaccine Market Size by Country (2021–2026)

10.4 Middle East & Africa Peptide Cancer Vaccine Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Boston Biomedical

11.1.1 Boston Biomedical Company Details

11.1.2 Boston Biomedical Business Overview

11.1.3 Boston Biomedical Peptide Cancer Vaccine Introduction

11.1.4 Boston Biomedical Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.1.5 Boston Biomedical Recent Development

11.2 Ultimovacs

11.2.1 Ultimovacs Company Details

11.2.2 Ultimovacs Business Overview

11.2.3 Ultimovacs Peptide Cancer Vaccine Introduction

11.2.4 Ultimovacs Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.2.5 Ultimovacs Recent Development

11.3 BrightPath Biotherapeutics

11.3.1 BrightPath Biotherapeutics Company Details

11.3.2 BrightPath Biotherapeutics Business Overview

11.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Introduction

11.3.4 BrightPath Biotherapeutics Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.3.5 BrightPath Biotherapeutics Recent Development

11.4 TapImmune

11.4.1 TapImmune Company Details

11.4.2 TapImmune Business Overview

11.4.3 TapImmune Peptide Cancer Vaccine Introduction

11.4.4 TapImmune Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.4.5 TapImmune Recent Development

11.5 Immatics

11.5.1 Immatics Company Details

11.5.2 Immatics Business Overview

11.5.3 Immatics Peptide Cancer Vaccine Introduction

11.5.4 Immatics Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.5.5 Immatics Recent Development

11.6 Sellas

11.6.1 Sellas Company Details

11.6.2 Sellas Business Overview

11.6.3 Sellas Peptide Cancer Vaccine Introduction

11.6.4 Sellas Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.6.5 Sellas Recent Development

11.7 Imugene

11.7.1 Imugene Company Details

11.7.2 Imugene Business Overview

11.7.3 Imugene Peptide Cancer Vaccine Introduction

11.7.4 Imugene Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.7.5 Imugene Recent Development

11.8 VAXON Biotech

11.8.1 VAXON Biotech Company Details

11.8.2 VAXON Biotech Business Overview

11.8.3 VAXON Biotech Peptide Cancer Vaccine Introduction

11.8.4 VAXON Biotech Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.8.5 VAXON Biotech Recent Development

11.9 Generex Biotechnology

11.9.1 Generex Biotechnology Company Details

11.9.2 Generex Biotechnology Business Overview

11.9.3 Generex Biotechnology Peptide Cancer Vaccine Introduction

11.9.4 Generex Biotechnology Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.9.5 Generex Biotechnology Recent Development

11.10 ISA Pharmaceuticals

11.10.1 ISA Pharmaceuticals Company Details

11.10.2 ISA Pharmaceuticals Business Overview

11.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Introduction

11.10.4 ISA Pharmaceuticals Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.10.5 ISA Pharmaceuticals Recent Development

11.11 OncoTherapy Science

11.11.1 OncoTherapy Science Company Details

11.11.2 OncoTherapy Science Business Overview

11.11.3 OncoTherapy Science Peptide Cancer Vaccine Introduction

11.11.4 OncoTherapy Science Revenue in Peptide Cancer Vaccine Business (2021–2026)

11.11.5 OncoTherapy Science Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

List of Tables

Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of ITK-1

Table 3. Key Players of GRN-1201

Table 4. Key Players of TPIV200

Table 5. Key Players of TPIV110

Table 6. Key Players of UV1

Table 7. Key Players of Galinpepimut-S

Table 8. Key Players of TARP 27-35

Table 9. Global Peptide Cancer Vaccine Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 10. Global Peptide Cancer Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 11. Global Peptide Cancer Vaccine Market Size by Region (US$ Million), 2021–2026

Table 12. Global Peptide Cancer Vaccine Market Share by Region (2021–2026)

Table 13. Global Peptide Cancer Vaccine Forecasted Market Size by Region (US$ Million), 2027–2032

Table 14. Global Peptide Cancer Vaccine Market Share by Region (2027–2032)

Table 15. Peptide Cancer Vaccine Market Trends

Table 16. Peptide Cancer Vaccine Market Drivers

Table 17. Peptide Cancer Vaccine Market Challenges

Table 18. Peptide Cancer Vaccine Market Restraints

Table 19. Global Peptide Cancer Vaccine Revenue by Players (US$ Million), 2021–2026

Table 20. Global Peptide Cancer Vaccine Market Share by Players (2021–2026)

Table 21. Global Top Peptide Cancer Vaccine Players by Tier (Tier 1, Tier 2, and Tier 3), based on Peptide Cancer Vaccine Revenue, 2025

Table 22. Ranking of Global Top Peptide Cancer Vaccine Companies by Revenue (US$ Million) in 2025

Table 23. Global 5 Largest Players Market Share by Peptide Cancer Vaccine Revenue (CR5 and HHI), 2021–2026

Table 24. Global Key Players of Peptide Cancer Vaccine, Headquarters and Area Served

Table 25. Global Key Players of Peptide Cancer Vaccine, Products and Applications

Table 26. Global Key Players of Peptide Cancer Vaccine, Date of General Availability (GA)

Table 27. Mergers and Acquisitions, Expansion Plans

Table 28. Global Peptide Cancer Vaccine Market Size by Pipeline (US$ Million), 2021–2026

Table 29. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2021–2026)

Table 30. Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (US$ Million), 2027–2032

Table 31. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2027–2032)

Table 32. Global Peptide Cancer Vaccine Market Size by Application (US$ Million), 2021–2026

Table 33. Global Peptide Cancer Vaccine Revenue Market Share by Application (2021–2026)

Table 34. Global Peptide Cancer Vaccine Forecasted Market Size by Application (US$ Million), 2027–2032

Table 35. Global Peptide Cancer Vaccine Revenue Market Share by Application (2027–2032)

Table 36. North America Peptide Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. North America Peptide Cancer Vaccine Market Size by Country (US$ Million), 2021–2026

Table 38. North America Peptide Cancer Vaccine Market Size by Country (US$ Million), 2027–2032

Table 39. Europe Peptide Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 40. Europe Peptide Cancer Vaccine Market Size by Country (US$ Million), 2021–2026

Table 41. Europe Peptide Cancer Vaccine Market Size by Country (US$ Million), 2027–2032

Table 42. Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 43. Asia-Pacific Peptide Cancer Vaccine Market Size by Region (US$ Million), 2021–2026

Table 44. Asia-Pacific Peptide Cancer Vaccine Market Size by Region (US$ Million), 2027–2032

Table 45. Latin America Peptide Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Latin America Peptide Cancer Vaccine Market Size by Country (US$ Million), 2021–2026

Table 47. Latin America Peptide Cancer Vaccine Market Size by Country (US$ Million), 2027–2032

Table 48. Middle East & Africa Peptide Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 49. Middle East & Africa Peptide Cancer Vaccine Market Size by Country (US$ Million), 2021–2026

Table 50. Middle East & Africa Peptide Cancer Vaccine Market Size by Country (US$ Million), 2027–2032

Table 51. Boston Biomedical Company Details

Table 52. Boston Biomedical Business Overview

Table 53. Boston Biomedical Peptide Cancer Vaccine Product

Table 54. Boston Biomedical Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 55. Boston Biomedical Recent Development

Table 56. Ultimovacs Company Details

Table 57. Ultimovacs Business Overview

Table 58. Ultimovacs Peptide Cancer Vaccine Product

Table 59. Ultimovacs Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 60. Ultimovacs Recent Development

Table 61. BrightPath Biotherapeutics Company Details

Table 62. BrightPath Biotherapeutics Business Overview

Table 63. BrightPath Biotherapeutics Peptide Cancer Vaccine Product

Table 64. BrightPath Biotherapeutics Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 65. BrightPath Biotherapeutics Recent Development

Table 66. TapImmune Company Details

Table 67. TapImmune Business Overview

Table 68. TapImmune Peptide Cancer Vaccine Product

Table 69. TapImmune Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 70. TapImmune Recent Development

Table 71. Immatics Company Details

Table 72. Immatics Business Overview

Table 73. Immatics Peptide Cancer Vaccine Product

Table 74. Immatics Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 75. Immatics Recent Development

Table 76. Sellas Company Details

Table 77. Sellas Business Overview

Table 78. Sellas Peptide Cancer Vaccine Product

Table 79. Sellas Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 80. Sellas Recent Development

Table 81. Imugene Company Details

Table 82. Imugene Business Overview

Table 83. Imugene Peptide Cancer Vaccine Product

Table 84. Imugene Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 85. Imugene Recent Development

Table 86. VAXON Biotech Company Details

Table 87. VAXON Biotech Business Overview

Table 88. VAXON Biotech Peptide Cancer Vaccine Product

Table 89. VAXON Biotech Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 90. VAXON Biotech Recent Development

Table 91. Generex Biotechnology Company Details

Table 92. Generex Biotechnology Business Overview

Table 93. Generex Biotechnology Peptide Cancer Vaccine Product

Table 94. Generex Biotechnology Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 95. Generex Biotechnology Recent Development

Table 96. ISA Pharmaceuticals Company Details

Table 97. ISA Pharmaceuticals Business Overview

Table 98. ISA Pharmaceuticals Peptide Cancer Vaccine Product

Table 99. ISA Pharmaceuticals Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 100. ISA Pharmaceuticals Recent Development

Table 101. OncoTherapy Science Company Details

Table 102. OncoTherapy Science Business Overview

Table 103. OncoTherapy Science Peptide Cancer Vaccine Product

Table 104. OncoTherapy Science Revenue in Peptide Cancer Vaccine Business (US$ Million), 2021–2026

Table 105. OncoTherapy Science Recent Development

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

Table 109. Authors List of This Report

List of Figures

Figure 1. Peptide Cancer Vaccine Picture

Figure 2. Global Peptide Cancer Vaccine Market Size Comparison by Pipeline (US$ Million), 2021–2032

Figure 3. Global Peptide Cancer Vaccine Market Share by Pipeline: 2025 vs 2032

Figure 4. ITK-1 Features

Figure 5. GRN-1201 Features

Figure 6. TPIV200 Features

Figure 7. TPIV110 Features

Figure 8. UV1 Features

Figure 9. Galinpepimut-S Features

Figure 10. TARP 27-35 Features

Figure 11. HER-Vaxx Features

Figure 12. Vx-001 Features

Figure 13. Global Peptide Cancer Vaccine Market Size by Application (US$ Million), 2021–2032

Figure 14. Global Peptide Cancer Vaccine Market Share by Application: 2025 vs 2032

Figure 15. Breast Cancer Case Studies

Figure 16. Lung Cancer Case Studies

Figure 17. Melanoma Case Studies

Figure 18. Prostate Cancer Case Studies

Figure 19. Others Case Studies

Figure 20. Peptide Cancer Vaccine Report Years Considered

Figure 21. Global Peptide Cancer Vaccine Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 22. Global Peptide Cancer Vaccine Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 23. Global Peptide Cancer Vaccine Market Share by Region: 2025 vs 2032

Figure 24. Global Peptide Cancer Vaccine Market Share by Players in 2025

Figure 25. Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 26. The Top 10 and 5 Players Market Share by Peptide Cancer Vaccine Revenue in 2025

Figure 27. North America Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. North America Peptide Cancer Vaccine Market Share by Country (2021–2032)

Figure 29. United States Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Canada Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Europe Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Europe Peptide Cancer Vaccine Market Share by Country (2021–2032)

Figure 33. Germany Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. France Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. U.K. Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Italy Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Russia Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Ireland Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Asia-Pacific Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Asia-Pacific Peptide Cancer Vaccine Market Share by Region (2021–2032)

Figure 41. China Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Japan Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. South Korea Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Southeast Asia Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. India Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Australia & New Zealand Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Latin America Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Latin America Peptide Cancer Vaccine Market Share by Country (2021–2032)

Figure 49. Mexico Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Brazil Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Middle East & Africa Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 52. Middle East & Africa Peptide Cancer Vaccine Market Share by Country (2021–2032)

Figure 53. Israel Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. Saudi Arabia Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. UAE Peptide Cancer Vaccine Market Size YoY Growth (US$ Million), 2021–2032

Figure 56. Boston Biomedical Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 57. Ultimovacs Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 58. BrightPath Biotherapeutics Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 59. TapImmune Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 60. Immatics Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 61. Sellas Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 62. Imugene Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 63. VAXON Biotech Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 64. Generex Biotechnology Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 65. ISA Pharmaceuticals Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 66. OncoTherapy Science Revenue Growth Rate in Peptide Cancer Vaccine Business (2021–2026)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Peptide Vaccine for Tumor Market Research Report 2024

Global Peptide Based Cancer Therapeutics Market Research Report 2024

Global Polypeptide Vaccine Market Research Report 2024

Peptide Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Tumor Targeting Peptides Market Research Report 2024

Global Adjuvant Peptide Market Research Report 2024

Synthetic Peptide Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide Therapy Market Research Report 2025

Peptide Based Drug Delivery System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Tumour cell Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Therapeutic Cancer Vaccines Market Research Report 2024

Global Cancer Immunotherapies Market Insights Forecast to 2030

Recombinant Peptide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Molecular Cancer Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide based Generics Market Research Report 2024

Global Cancer Immunotherapy Market Insights Forecast to 2030

Global Emerging Cancer Vaccines Market Insights Forecast to 2030

Global Immuno oncology Clinical Trials Market Research Report 2024

Prostate Cancer Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions